Vivek Kaul, MD

In the final episode, each panelist synthesizes their top recommendations for advancing EPI care.

This episode spotlights a recent publication by Ashkar and colleagues—co-authored by Jennifer Geremia—surveying prescribing practices for EPI across a broad cross-section of healthcare professionals.

Clinicians reveal where pancreatic care falls apart—diagnosis delays, post-discharge gaps, lost oncology follow-up—and how to fix handoffs fast.

Why EPI outcomes improve when GI, primary care, nutrition and pain teams coordinate—streamlining labs, vitamins and follow-ups for patients.

Learn how clinicians tailor pancreatic enzyme therapy: insurance, dosing, PPIs, and fixes for nonresponse—plus limits of OTC enzymes.

Learn what happens after suspected EPI: patient education, enzyme therapy tips, nutrition and vitamin checks, plus smoking and alcohol support.

Clinicians weigh PEI questionnaires, symptom scores, and AGA updates to track exocrine pancreatic insufficiency and tailor patient-centered care.

Learn a stepwise approach to evaluating EPI-like diarrhea—history, alarm features, fecal elastase and imaging—to rule out IBS, celiac, IBD.

Learn how primary care, APPs, and specialists collaborate to spot symptoms, refer fast, and follow guidelines for accurate GI diagnosis.

Clinicians across specialties spot red flags, refer early to GI, and follow guidelines to improve diagnosis and management.

Why EPI stays missed: barriers to enzyme therapy, targeted fecal elastase testing, and preventing malnutrition, bone loss, and QoL decline.

Panelists discuss the wide range of pancreatic and non-pancreatic conditions that increase suspicion for exocrine pancreatic insufficiency to improve identification of high-risk patients.

Panelists discuss recognizing the varied and often atypical symptoms of exocrine pancreatic insufficiency to improve early diagnosis and clinical awareness.

Vivek Kaul, MD, discusses how primary care providers can effectively communicate the importance of colorectal cancer screening and guide patients in selecting the most suitable option, and the significant role of patient preferences and adherence in this decision-making process, while also addressing future innovations in screening methods.

Vivek Kaul, MD, discusses the sensitivity and accuracy of the stool DNA test, providing relevant data, while also describing the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests.

Vivek Kaul, MD, discusses the benefits of using a stool DNA test for colorectal cancer screening, emphasizing its sensitivity, guideline recommendations, and its potential to reduce the screening burden for patients, as well as explaining the test's mechanism of action.

Vivek Kaul, MD, discusses the various options available for colorectal cancer screening, providing an overview of stool-based tests, blood-based tests, colonoscopy, and emerging screening methods.

Vivek Kaul, MD, discusses how colorectal cancer screening is essential for early detection and prevention of late-stage disease, including the current US Preventative Services Task Force (USPSTF) guidelines on when to initiate screening and the recommended intervals that vary by screening method.